Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Omalizumab (Xolair) for cholinergic urticaria
2013-002770-43Phase 2Completed
- Sponsor
- Clínica Universidad de Navarra
- Start
- Aug 2013
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Cholinergic Urticaria (CU) comparing Omalizumab with Placebo (2 arms). Primary endpoint: Negativization of the exercise challenge test. Started Aug 2013; status: completed.
02
Drugs
omalizumab
03
Conditions
Cholinergic Urticaria (CU)
Beyond the preview
Go deeper on 2013-002770-43.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-002770-43.